In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Eliane Hadas YardeniDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0009-0007-3898-5035 Dóra Judit KissMedicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0002-6664-3872 Julie SanchezDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK.ORCID 0000-0002-5765-4342 Keshet ShavitDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-1343-2481 Dénes Szepesi KovácsMedicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Attila EgyedMedicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0001-8463-4219 Caleb D VogtMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Supriya A GaitondeInstitute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.
Jacqueline GlennDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK.ORCID 0009-0008-0608-2744 Meritxell CanalsDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK.ORCID 0000-0002-7942-5006 Michel BouvierInstitute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.ORCID 0000-0003-1128-0100 Amy Hauck NewmanMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.ORCID 0000-0001-9065-4072 J Robert LaneDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK.ORCID 0000-0002-7361-7875 György M KeserűMedicinal Chemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0003-1039-7809 Moran Shalev-BenamiDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-6902-1924 Funding
NOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8MIntramural NIH HHS Z01 DA000424
6 · The paper itselfAbstract
The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D
Indexed as
Dopamine AgonistsPiperazinesReceptors, Dopamine D3Antipsychotic AgentsBinding SitesCryoelectron MicroscopyDrug Partial AgonismHumansLigandsMolecular Dynamics SimulationProtein BindingAntipsychotic AgentscariprazineDopamine AgonistsLigandsPiperazinesReceptors, Dopamine D3
Identifiers
PMID42664351
PMCPMC13524052
What OpenQuestion holds
Textmetadata
Read underepoch 390